Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice
暂无分享,去创建一个
P. Fitzpatrick | S. Bunting | Catherine Vitelli | Sherry Bullens | J. LeBowitz | R. Lawrence | Bryan K. Yip | Jon Vincelette | G. Yogalingam | M. Aoyagi-Scharber | P. Tiger | B. E. Crawford | Melanie J. Lo | Terri M. Christianson | Jeremy L. Van Vleet | Brian Baridon | O. Gorostiza | John Holtzinger | Danielle Crippen-Harmon | Evan G. Adintori | B. Yates | Heather Prill | Amanda R. Lee | Wesley C. Minto | Sara Rigney | S. Bullens | B. Baridon | B. Crawford | J. Lebowitz | Pascale M. N. Tiger
[1] G. Węgrzyn,et al. Glycosaminoglycans and mucopolysaccharidosis type III. , 2016, Frontiers in bioscience.
[2] P. Gissen,et al. Intracerebroventricular Cerliponase Alfa (BMN 190) in Children with CLN2 Disease: Interim Results from a Phase 1/2, Open-Label, Dose-Escalation Study , 2016 .
[3] W. Pardridge,et al. Insulin Receptor Antibody-α-N-Acetylglucosaminidase Fusion Protein Penetrates the Primate Blood-Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type B Fibroblasts. , 2016, Molecular pharmaceutics.
[4] P. Fitzpatrick,et al. Histologic characterization of the progression of central nervous system pathology in the mucopolysaccharidosis IIIB (MPS IIIB, Sanfilippo syndrome type B) mouse model and bio-distribution and efficacy of the intracerebroventricular enzyme replacement therapy, BMN 250 , 2016 .
[5] L. Lue,et al. Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains , 2015, Alzheimer's Research & Therapy.
[6] V. Haurigot,et al. Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy. , 2015, Human molecular genetics.
[7] P. Trim,et al. Delivery of therapeutic protein for prevention of neurodegenerative changes: Comparison of different CSF-delivery methods , 2015, Experimental Neurology.
[8] W. Banks,et al. Intrathecal delivery of protein therapeutics to the brain: a critical reassessment. , 2014, Pharmacology & therapeutics.
[9] P. Fitzpatrick,et al. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB , 2014, Proceedings of the National Academy of Sciences.
[10] C. Heldermon,et al. Mucopolysaccharidosis III (Sanfilippo Syndrome)- disease presentation and experimental therapies. , 2014, Pediatric endocrinology reviews : PER.
[11] P. Dickson,et al. Insulin-like growth factor II peptide fusion enables uptake and lysosomal delivery of α-N-acetylglucosaminidase to mucopolysaccharidosis type IIIB fibroblasts. , 2014, The Biochemical journal.
[12] J. Esko,et al. Glycan-based biomarkers for mucopolysaccharidoses. , 2014, Molecular genetics and metabolism.
[13] A. Quinn,et al. SBC-103, a recombinant human alpha-N-acetylglucosaminidase, demonstrates mannose-6-phosphate receptor dependent transport in an in vitro blood-brain barrier model , 2014 .
[14] P. Fitzpatrick,et al. Engineering of a recombinant NAGLU fusion protein with insulin-like growth factor 2 leads to improved cellular uptake via a glycosylation-independent lysosomal targeting pathway , 2014 .
[15] John L. Orrock,et al. Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice , 2013, Gene Therapy.
[16] B. Byrne,et al. Glycosylation-independent Lysosomal Targeting of Acid α-Glucosidase Enhances Muscle Glycogen Clearance in Pompe Mice* , 2012, The Journal of Biological Chemistry.
[17] Kevin W Eliceiri,et al. NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.
[18] J. Cooper,et al. Neuropathology in Mouse Models of Mucopolysaccharidosis Type I, IIIA and IIIB , 2012, PloS one.
[19] S. Fumagalli,et al. Temporal pattern of expression and colocalization of microglia/macrophage phenotype markers following brain ischemic injury in mice , 2011, Journal of Neuroinflammation.
[20] E. Neufeld,et al. Defects in the Medial Entorhinal Cortex and Dentate Gyrus in the Mouse Model of Sanfilippo Syndrome Type B , 2011, PloS one.
[21] J. Esko,et al. Disease-Specific Non-Reducing End Carbohydrate Biomarkers for Mucopolysaccharidoses , 2011, Nature chemical biology.
[22] F. Wijburg,et al. Mucopolysaccharidosis type III (Sanfilippo Syndrome): emerging treatment strategies. , 2011, Current Pharmaceutical Biotechnology.
[23] H. Fu,et al. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[24] S. Raoul,et al. Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[25] Carmela Di Domenico,et al. Serum MIP-1 α level: a biomarker for the follow-up of lentiviral therapy in mucopolysaccharidosis IIIB mice , 2010, Journal of Inherited Metabolic Disease.
[26] L. Kudo,et al. Sanfilippo syndrome type B, a lysosomal storage disease, is also a tauopathy , 2009, Proceedings of the National Academy of Sciences.
[27] Frederico A. C. Azevedo,et al. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled‐up primate brain , 2009, The Journal of comparative neurology.
[28] J. Hopwood,et al. Examination of intravenous and intra‐CSF protein delivery for treatment of neurological disease , 2009, The European journal of neuroscience.
[29] Roger Lawrence,et al. Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans , 2008, Nature Methods.
[30] B. Poorthuis,et al. Sanfilippo syndrome: A mini-review , 2008, Journal of Inherited Metabolic Disease.
[31] D. Dickson,et al. Actin-binding Proteins Coronin-1a and IBA-1 are Effective Microglial Markers for Immunohistochemistry , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[32] M. Mcentee,et al. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. , 2007, Molecular genetics and metabolism.
[33] S. Ryazantsev,et al. Lysosomal accumulation of SCMAS (subunit c of mitochondrial ATP synthase) in neurons of the mouse model of mucopolysaccharidosis III B. , 2007, Molecular genetics and metabolism.
[34] A. Cressant,et al. Improved Behavior and Neuropathology in the Mouse Model of Sanfilippo Type IIIB Disease after Adeno-Associated Virus-Mediated Gene Transfer in the Striatum , 2004, The Journal of Neuroscience.
[35] W. Mobley,et al. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. , 2004, Molecular genetics and metabolism.
[36] W. Sly,et al. Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[37] S. Kar,et al. Insulin‐like growth factor‐II/mannose‐6‐phosphate receptor: Widespread distribution in neurons of the central nervous system including those expressing cholinergic phenotype , 2003, The Journal of comparative neurology.
[38] S. Ryazantsev,et al. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[39] M. Fanselow,et al. Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[40] M. Alexander,et al. Principles of Neural Science , 1981 .
[41] A. Fensom,et al. 4‐methylumbelliferyl α‐N‐acetylglucosaminidase activity for diagnosis of Sanfilippo B disease , 1985 .
[42] K. Vonfigura. Human alpha-n-acetylglucosaminidase. 2. Activity towards natural substrates and multiple recognition forms. , 1977 .
[43] R. Giugliani,et al. The mucopolysaccharidoses. , 1976, Journal of medical genetics.
[44] R. Crystal,et al. Intracerebral administration of rAAV2/5hNAGLU vector in children with MPS IIIB: results at 30 months of a phase I/II trial , 2017 .
[45] J. Hopwood,et al. Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases. , 2009, International journal of clinical pharmacology and therapeutics.
[46] A. Fensom,et al. 4-Methylumbelliferyl alpha-N-acetylglucosaminidase activity for diagnosis of Sanfilippo B disease. , 1985, Clinical genetics.
[47] K. von Figura. Human alpha-n-acetylglucosaminidase. 2. Activity towards natural substrates and multiple recognition forms. , 1977, European journal of biochemistry.
[48] Anthony O. Fedele. The Application of Clinical Genetics Dovepress Sanfilippo Syndrome: Causes, Consequences, and Treatments , 2022 .